MD4626B1 - Derivaţi de tamoxifen pentru tratamentul afecţiunilor neoplazice, în special cu nivel înalt de proteină HER2 - Google Patents

Derivaţi de tamoxifen pentru tratamentul afecţiunilor neoplazice, în special cu nivel înalt de proteină HER2

Info

Publication number
MD4626B1
MD4626B1 MDA20150117A MD20150117A MD4626B1 MD 4626 B1 MD4626 B1 MD 4626B1 MD A20150117 A MDA20150117 A MD A20150117A MD 20150117 A MD20150117 A MD 20150117A MD 4626 B1 MD4626 B1 MD 4626B1
Authority
MD
Moldova
Prior art keywords
tamoxifen
treatment
neoplastic diseases
her2 protein
general formula
Prior art date
Application number
MDA20150117A
Other languages
English (en)
Russian (ru)
Other versions
MD20150117A2 (ro
MD4626C1 (ro
Inventor
Ян Штурса
Лукаш Вернер
Иржи Неужиль
Original Assignee
Smart Brain s.r.o.
Biotechnologicky Ustav Av Cr V.V0
Иржи Неужиль
Kkcg Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50677895&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4626(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CZ2013-308A external-priority patent/CZ304553B6/cs
Priority claimed from CZ2014-66A external-priority patent/CZ305571B6/cs
Application filed by Smart Brain s.r.o., Biotechnologicky Ustav Av Cr V.V0, Иржи Неужиль, Kkcg Ag filed Critical Smart Brain s.r.o.
Publication of MD20150117A2 publication Critical patent/MD20150117A2/ro
Publication of MD4626B1 publication Critical patent/MD4626B1/ro
Publication of MD4626C1 publication Critical patent/MD4626C1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5449—Polyphosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/14—Styryl dyes
    • C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/008—Dyes containing a substituent, which contains a silicium atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)

Abstract

Prezenta invenţie se referă la noi izomeri E/Z direcţionaţi mitocondrial ai derivaţilor de trifenilfosfoniu alifatic ai tamoxifenului, în care lanţul alifatic este alchil sau alchenil, şi la sărurile aminice terţiare corespunzătoare ale acestora, şi/sau la amestecurile acestora (MitoTax). Derivaţii de alchil trifenilfosfoniu ai tamoxifenului au formula generală (I):I,în care n = 8…12 şi Z este selectat dintr-o grupă de săruri organice sau anorganice.Derivaţii de alchenil trifenilfosfoniu ai tamoxifenului au formula generală IA:IA,în care n = 6…10 şi Z are semnificaţiile definite mai sus.Aceşti compuşi sunt aplicabili pentru tratamentul bolilor neoplazice, în special al celor cu niveluri înalte de proteină HER2. Medicamentul pentru tratamentul bolilor neoplazice, conform prezentei invenţii, conţine cel puţin un izomer E/Z al derivaţilor de trifenilfosfoniu alifatic ai tamoxifenului cu formula generală (I) şi/sau IA, sau sărurile lor corespunzătoare ale aminelor terţiare.
MD20150117A 2013-04-24 2014-04-07 Derivaţi de tamoxifen pentru tratamentul afecţiunilor neoplazice, în special cu nivel înalt de proteină HER2 MD4626C1 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CZ2013-308A CZ304553B6 (cs) 2013-04-24 2013-04-24 Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
CZ2014-66A CZ305571B6 (cs) 2014-01-29 2014-01-29 Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
PCT/CZ2014/000035 WO2014173374A1 (en) 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level

Publications (3)

Publication Number Publication Date
MD20150117A2 MD20150117A2 (ro) 2016-08-31
MD4626B1 true MD4626B1 (ro) 2019-04-30
MD4626C1 MD4626C1 (ro) 2019-11-30

Family

ID=50677895

Family Applications (1)

Application Number Title Priority Date Filing Date
MD20150117A MD4626C1 (ro) 2013-04-24 2014-04-07 Derivaţi de tamoxifen pentru tratamentul afecţiunilor neoplazice, în special cu nivel înalt de proteină HER2

Country Status (22)

Country Link
US (1) US9896466B2 (ro)
EP (1) EP2989110B1 (ro)
JP (1) JP6375091B2 (ro)
KR (1) KR101764991B1 (ro)
CN (1) CN105452265B (ro)
AU (1) AU2014256546B2 (ro)
CA (1) CA2909994C (ro)
CY (1) CY1120821T1 (ro)
DK (1) DK2989110T3 (ro)
EA (1) EA029881B1 (ro)
ES (1) ES2699099T3 (ro)
GE (1) GEP20186868B (ro)
HK (1) HK1216317A1 (ro)
HR (1) HRP20181872T1 (ro)
HU (1) HUE042239T2 (ro)
MD (1) MD4626C1 (ro)
NZ (1) NZ713589A (ro)
PL (1) PL2989110T3 (ro)
PT (1) PT2989110T (ro)
SI (1) SI2989110T1 (ro)
UA (1) UA116469C2 (ro)
WO (1) WO2014173374A1 (ro)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3317272T3 (pl) * 2015-07-03 2020-01-31 Bayer Cropscience Aktiengesellschaft Chwastobójczo skuteczne pochodne N-(1,3,4-oksadiazol-2-ilo)arylokarboksyamidowe
EP3317268B1 (de) * 2015-07-03 2019-08-28 Bayer CropScience Aktiengesellschaft Herbizid wirksame n-(tetrazol-5-yl)- und n-(triazol-5-yl)arylcarboxamid-derivate
CA3030411A1 (en) * 2016-07-12 2018-01-18 Accutar Biotechnology Inc. Novel compounds and uses thereof
CA3032153A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
EP3330274A1 (en) * 2016-12-01 2018-06-06 Springtide Ventures s.r.o. Compounds for treatment of senescence-related disorders
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
KR20200010343A (ko) 2017-05-19 2020-01-30 루넬라 바이오테크 인코포레이티드 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제
US11497749B2 (en) 2017-10-24 2022-11-15 Lunella Biotech, Inc. Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (CSCS) by inhibiting mitochondrial respiration
US10980821B2 (en) 2017-11-24 2021-04-20 Lunella Biotech, Inc. Triphenylphosphonium-derivative compounds for eradicating cancer stem cells
CA3083487A1 (en) 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US11541120B2 (en) 2017-12-05 2023-01-03 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
WO2019126179A1 (en) 2017-12-20 2019-06-27 Lunella Biotech, Inc. Targeting mitochondrial fission through mdivi-1 derivatives
EP3955935A4 (en) * 2019-04-16 2023-01-18 Lunella Biotech, Inc. ALKYL-TPP COMPOUNDS FOR MITOCHONDRIA TARGETING AND CANCER THERAPIES
EP3753944A1 (en) 2019-06-17 2020-12-23 Institute Of Biotechnology Cas, V.V.I. 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1289570C (en) * 1986-06-16 1991-09-24 Tetsuji Asao 1,1,2-triaryl-1-alkene derivatives
CA2092996A1 (en) * 1990-10-01 1992-04-02 David Yang High affinity tamoxifen derivatives and uses thereof
JP3635708B2 (ja) * 1995-03-06 2005-04-06 出光興産株式会社 有機エレクトロルミネッセンス素子
TWI309571B (en) * 2002-12-31 2009-05-11 Ind Tech Res Inst Delivery carrier for targeting cells haring over-expressed estrogen
US7888335B2 (en) * 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
CN1997403A (zh) * 2004-07-13 2007-07-11 奥里迪斯生物医学研究及开发有限责任公司 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途
USRE47300E1 (en) * 2008-03-14 2019-03-19 Cancure Limited Mitochondrially delivered anti-cancer compounds
US20100297262A1 (en) * 2009-04-17 2010-11-25 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
WO2011129837A1 (en) * 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer

Also Published As

Publication number Publication date
JP2016522179A (ja) 2016-07-28
MD20150117A2 (ro) 2016-08-31
JP6375091B2 (ja) 2018-08-15
PL2989110T3 (pl) 2019-03-29
GEP20186868B (en) 2018-06-25
HRP20181872T1 (hr) 2019-02-08
US9896466B2 (en) 2018-02-20
ES2699099T3 (es) 2019-02-07
AU2014256546B2 (en) 2017-03-30
CN105452265B (zh) 2017-05-10
EP2989110B1 (en) 2018-08-08
EA201591918A1 (ru) 2016-02-29
US20160075726A1 (en) 2016-03-17
KR20150144756A (ko) 2015-12-28
PT2989110T (pt) 2018-11-15
CA2909994A1 (en) 2014-10-30
CY1120821T1 (el) 2019-12-11
AU2014256546A1 (en) 2015-11-12
HUE042239T2 (hu) 2019-06-28
UA116469C2 (uk) 2018-03-26
NZ713589A (en) 2017-12-22
KR101764991B1 (ko) 2017-08-10
EA029881B1 (ru) 2018-05-31
EP2989110A1 (en) 2016-03-02
CN105452265A (zh) 2016-03-30
CA2909994C (en) 2018-06-26
HK1216317A1 (zh) 2016-11-04
SI2989110T1 (sl) 2019-01-31
DK2989110T3 (en) 2018-12-03
WO2014173374A1 (en) 2014-10-30
MD4626C1 (ro) 2019-11-30

Similar Documents

Publication Publication Date Title
MD4626B1 (ro) Derivaţi de tamoxifen pentru tratamentul afecţiunilor neoplazice, în special cu nivel înalt de proteină HER2
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
CO2018011550A2 (es) Compuestos de pirrolotriazina como inhibidores de tam
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
BR112018007381A2 (pt) compostos úteis como imunomoduladores
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
DOP2017000066A (es) Compuestos y composiciones como inhibidores de quinasa raf
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
BR112017003975A2 (pt) composição de conjugado de ligante e fármaco, e, composto ligador de fármaco.
BR112015023753A2 (pt) composições, formulações e métodos para o tratamento de doenças oculares
DOP2017000278A (es) Piridinas sustituidas y método de uso
UY35737A (es) Pesticidas de azol bicíclico sustituido con heterociclos
CR20160478A (es) Composición de control de enfermedades de plantas y método para controlar enfermedades de plantas mediante su aplicación
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
DOP2017000107A (es) Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
CL2020001047A1 (es) Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma.
MX2018008671A (es) Composicion para incrementar la expresion de pgc-1alfa.
DOP2016000211A (es) Pirazinas moduladoras de gpr6
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.

Legal Events

Date Code Title Description
FG4A Patent for invention issued